Product Details
Price of Gleevec in India in Beijing,
Latest price of Gleevec in India
New version of Gleevec price in India
Purchasing price of Gleevec in India
Cash on delivery, conscientious medicine, selling Fake medicine kills whole family. Order Hotline 3 Ms. Wang
Usage and Dosage Edit
Starting dose: For patients with chronic myeloid leukemia in the blast phase and accelerated phase, the recommended dose of imatinib mesylate is/day; for patients who fail interferon treatment For patients in the chronic phase, as well as for patients with malignant gastrointestinal stromal tumors that cannot be surgically removed or have metastasized, the recommended dose is/day, which is taken orally once a day. It is advisable to take the medicine with a meal and drink a large glass of water. As long as it is effective, It should be taken continuously.
If the blood picture permits and there are no serious adverse drug reactions, the dose may be considered to be increased from / day to / day, or from / day to / day (taken in divided doses) under the following circumstances: disease progression, treatment for at least 3 After several months, satisfactory hematological response could not be obtained, and the hematological response that had been achieved disappeared again.
The dose must be adjusted in the following circumstances: If serious non-hematological adverse reactions (such as severe water retention) occur during treatment, the drug should be discontinued until the adverse reactions disappear, and then the dose will be adjusted according to the severity of the adverse reactions.
Adjustment of dose in case of severe liver toxicity: If the increase in bilirubin exceeds 3 times the upper limit of the normal range or the increase in transaminases exceeds the upper limit of the normal range, the drug should be discontinued until the above indicators drop to the upper limit of the normal range respectively. Or . times or less.
Dose adjustment in neutropenia or thrombocytopenia: Acceleration phase or blast phase: If severe neutropenia and thrombocytopenia occur (neutrophils less than ./ and/or platelets less than /, the recommended dose Reduce to / day. If the blood cells continue to decrease for weeks, the dose should be further reduced to / day. If the blood cells continue to decrease for weeks, it is advisable to stop the drug until neutrophils / and platelets /. When used again, the dose is / day.
- Patients in the chronic phase after interferon treatment failure: it is advisable to stop taking the drug when the neutrophils are less than ./ and/or the platelets are less than /, and then resume the drug only when the neutrophils are ./ and the platelets are less than /, the dose is /day, such as When the neutrophils or platelets are reduced to the above values again, the dose is reduced to /day when the drug is resumed.
Dosage for patients with liver failure: The plasma concentration of imatinib mesylate in patients with liver failure can be Therefore, these patients should be cautious when using this drug. There are no clinical data on the use of imatinib mesylate in patients with liver damage, and no recommendations for dose adjustment can be made.
Dosage for patients with renal failure and elderly patients : It is known that creatinine clearance can decrease with aging, and age has no significant impact on the pharmacokinetics of imatinib mesylate. Since no clinical trials have been conducted in patients with renal impairment, dose adjustment cannot be proposed. Suggestions.
The sales areas are as follows
Hebei Shanxi Liaoning Jilin Heilongjiang Jiangsu Zhejiang Anhui Fujian Jiangxi Shandong Henan Hubei Hunan Guangdong Hainan Sichuan Guizhou Yunnan Shaanxi Gansu Qinghai Beijing Tianjin Shanghai Chongqing Xinjiang Guangxi Ningxia Inner Mongolia Tibet Beijing Shanghai Guangzhou, Shenzhen Tianjin Nanjing Wuhan Shenyang Xi'an Chengdu Chongqing Hangzhou Qingdao Dalian Ningbo Jinan Harbin Changchun Xiamen Zhengzhou Changsha Fuzhou Urumqi Kunming Lanzhou Suzhou Wuxi Nanchang Guiyang Nanning Hefei Taiyuan Shijiazhuang Hohhot Foshan Dongguan Tangshan Yantai Quanzhou Baotou
Disclaimer
The information/pictures/parameters, etc. displayed on this webpage about【Purchasing agent for Indian Gleevec 15011127273 for sale imatinib】are provided by member【Ankang Pharmaceutical Company
】,By Titker Trade Network members 【Ankang Pharmaceutical Company
】is solely responsible for the authenticity, accuracy and legality of the information/pictures/parameters, etc.,Titker Trade Network only provides display services. For your safety, please choose Titker Trade Network for online trading, otherwise Titker Trade Network will not bear any responsibility for this.
If your legitimate rights and interests have been infringed, please contact Titker Trade Network customer service as soon as possible. We will serve you wholeheartedly. Thank you for your attention and support to Titker Trade Network!